Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab.

J Rheumatol

From Rheumatology, Rheumazentrum Ruhrgebiet, Herne; Ruhr-University Bochum, Bochum; Radiology, Charité Universitätsmedizin, Berlin, Germany; Biostatistics, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA.J. Braun, MD, Department of Rheumatology, Rheumazentrum Ruhrgebiet, and Ruhr-University Bochum; X. Baraliakos, MD, Department of Rheumatology, Rheumazentrum Ruhrgebiet, and Ruhr-University Bochum; K.G. Hermann, MD, PhD, Radiology, Charité Universitätsmedizin; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; B. Hsu, MD, PhD, Immunology, Janssen Research & Development LLC.

Published: May 2016

Objective: To assess vascular endothelial growth factor (VEGF) correlations with new bone formation and bone marrow edema in patients with ankylosing spondylitis (AS) treated with golimumab (GOL).

Methods: Following placebo control (through weeks 16 and 24), GO-RAISE (A Multicenter Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondylitis; ClinicalTrials.gov: NCT00265083) all patients received GOL; sera/images were available at weeks 0, 104, and 208. Lateral spinal radiographs and magnetic resonance imaging (MRI) were scored using the modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) and the Ankylosing Spondylitis Spinal MRI activity score, respectively.

Results: VEGF levels and the mSASSS did not significantly correlate. Logistic regression analyses showed no association between VEGF levels and an increased risk of syndesmophyte formation at weeks 104 and 208. Pretreatment/Week 14 VEGF did not predict MRI scores/changes at Week 104.

Conclusion: Serum VEGF did not predict radiographic progression/spinal inflammation in patients receiving antitumor necrosis factor.

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.150897DOI Listing

Publication Analysis

Top Keywords

ankylosing spondylitis
20
vascular endothelial
8
endothelial growth
8
growth factor
8
active ankylosing
8
spondylitis treated
8
treated golimumab
8
weeks 104
8
104 208
8
vegf levels
8

Similar Publications

: The nuclear factor (NF)-kB essential modulator (NEMO) has a crucial role in the NFκB pathway. Hypomorphic pathogenic variants cause ectodermal dysplasia with immunodeficiency (EDA-ID) in affected males. However, heterozygous amorphic variants could be responsible for Incontinentia Pigmenti (IP) in female carriers.

View Article and Find Full Text PDF

: Ankylosing spondylitis (AS) is a chronic progressive inflammatory process of the axial skeleton and sacroiliac joints (SIJ). Symptoms typically appear between the ages of 20 and 40, although there are also cases of juvenile-onset AS. This suggests that most patients with AS are of reproductive age at the time of diagnosis.

View Article and Find Full Text PDF

Ankylosing spondylitis (AS) is a chronic inflammatory and autoimmune disease that primarily affects the sacroiliac joints and axial skeleton. While the exact pathogenetic mechanism of AS remains unclear, previous reports have highlighted the involvement of genetic factors, immune responses, and gut microbiota dysregulation in the development of this condition. Short-chain fatty acids (SCFAs), which are microbial fermentation products derived from sugar, protein, and dietary fibers, play a role in maintaining the intestinal barrier function and reducing inflammatory responses.

View Article and Find Full Text PDF

Objective: To describe the incidence rates of inflammatory bowel disease (IBD) and tuberculosis (TB) in Korean patients with ankylosing spondylitis receiving biologics.

Methods: Data from a Korean claims database between 2010 and 2021 was used to calculate crude incidence rates of TB and IBD using number of events and total patient-years (PYs).

Results: Overall, 43 643 and 43 396 patients were included in TB and IBD cohorts.

View Article and Find Full Text PDF

Clinical features of inflammatory arthritis in daily practice-China's perspective.

Clin Rheumatol

January 2025

Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.

Objective: This study aimed to analyze and compare the proportion of patients with different types of inflammatory arthritis and investigate the clinical characteristics, including symptoms and signs, medication choices, and disease activity, in the daily clinical practice of China.

Methods: Patients with inflammatory arthritis were recruited from 16 Grade-A tertiary hospitals between August 2021 and April 2022. The medical profiles, encompassing sociodemographic characteristics, clinical and laboratory date, were collected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!